AGP Executive Report
Last update: 10 minutes agoPTSD Treatment Update: A multicenter trial found pharmaceutical THC (dronabinol) oil drops were safe and effective at cutting PTSD-related nightmares, with over a third of patients reporting no nightmares after 10 weeks. CBD/THC Policy Clash: Pennsylvania AG Dave Sunday backed a hemp-derived THC product ban push, arguing it will clarify enforcement—while hemp businesses warn it could shut down legitimate operators. Texas Retail Fallout: A federal judge refused to pause Texas’s THC product ban for now, keeping restrictions in place as hemp retailers argue it harms interstate commerce. CHS/ER Pressure: New reporting highlights how frequent cannabis use is driving more ER visits for cannabis hyperemesis syndrome, including younger users. Medical Cannabis R&D: Artelo Biosciences enrolled its first patient in a Phase 2 glaucoma study of a synthetic cannabinoid receptor agonist aimed at lowering eye pressure without central side effects. Market Watch: A new report projects insulin delivery devices could nearly double to $74.39B by 2035, reflecting rising diabetes demand. Global Enforcement: Customs in Azerbaijan intercepted 25 kg of dried marijuana hidden in pepper shipments from Iran to Russia.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
